Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliparib SCHEMBL30418660 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29843298 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422320 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368887 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368883 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368889 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29455770 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5660 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104998-A1 | SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2026-05-21 | — | — | WO | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| WO-2026106315-A1 | METHOD FOR PROVIDING INFORMATION ON ATM GENE FUNCTION | 연세대학교 산학협력단 | 2026-05-21 | — | — | WO | claimed |
| WO-2026106998-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE | PURDUE RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4744665-A1 | COMBINATION OF POLQ INHIBITOR COMPOUND AND ANTI-CANCER THERAPEUTIC AGENT OR RADIOTHERAPY | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2025217307-A9 | METHODS FOR PREDICTING RESPONSE TO A RAS(ON) INHIBITOR AND COMBINATION THERAPIES | Revolution Medicines, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260130924-A1 | COMPOSITIONS AND METHODS OF TREATING SUBJECTS WITH BRCA1 MUTATION OR DEFICIENCY | UNIV TEXAS (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739678-A2 | AGE-MODULATING COMPOUNDS AND METHODS FOR MAKING AGE-MODULATED CELLS | Memorial Sloan Kettering Cancer Center (US) | 2026-05-13 | — | — | EP | claimed |
| EP-3693375-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2022-02-16 | — | — | EP | claimed |
| US-20220040134-A1 | ELECTROPHILES AND ELECTROPHILE PRO-DRUGS AS RAD51 INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022029223-A1 | COMBINATION THERAPY COMPRISING ANTI-KAAG1 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | ADC THERAPEUTICS SA (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| CN-113993510-A | Combination treatment regimen using 1,6-dibromo-1,6-dideoxy-dulcitol | 埃莱森制药有限责任公司 | 2022-01-28 | — | — | CN | claimed |
| US-20220025053-A1 | Methods of Inhibiting Metastasis in Cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-01-27 | — | — | US | claimed |
| US-20220023405-A1 | USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES | Mendus B.V. (NL) | 2022-01-27 | — | — | US | claimed |
| US-20220025468-A1 | HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY DETECTION | GUARDANT HEALTH, INC. | 2022-01-27 | — | — | US | claimed |
| WO-2022020218-A1 | DIAGNOSTIC METHODS FOR CANCER USING AXL DECOY RECEPTORS | ARAVIVE INC (US) | 2022-01-27 | — | — | WO | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |